Opus Genetics ( (IRD) ) has issued an update.
On April 2, 2025, Opus Genetics, Inc. announced the termination of its Purchase Agreement with Lincoln Park Capital Fund, LLC, which was initially established on August 10, 2023. The decision was influenced by current market dynamics, particularly the limited value of the facility due to the current market price of the company’s stock. Prior to the termination, Opus Genetics had issued 1,700,000 shares, generating approximately $5.2 million in net proceeds, leaving about $44.8 million in shares unsold under the agreement.
More about Opus Genetics
Opus Genetics, Inc. operates in the biotechnology industry, focusing on developing genetic therapies. The company is engaged in creating treatments for inherited retinal diseases, aiming to address unmet medical needs in this specialized market.
YTD Price Performance: -22.30%
Average Trading Volume: 206,498
Technical Sentiment Signal: Strong Buy
Current Market Cap: $44.57M
See more data about IRD stock on TipRanks’ Stock Analysis page.